Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANTONE OPEKUN and DAVID GRAHAM.
ANTONE OPEKUN
Connection Strength
5.965
DAVID GRAHAM
  1. Enzyme therapy for functional bowel disease-like post-prandial distress. J Dig Dis. 2018 Nov; 19(11):650-656.
    View in: PubMed
    Score: 0.647
  2. Brief report: Lactobacillus bulgaricus GLB44 (Proviotic? ) plus esomeprazole for Helicobacter pylori eradication: A pilot study. Helicobacter. 2018 Apr; 23(2):e12476.
    View in: PubMed
    Score: 0.623
  3. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010 Aug; 45(8):816-20.
    View in: PubMed
    Score: 0.358
  4. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Sep 01; 24(5):845-50.
    View in: PubMed
    Score: 0.281
  5. In vivo tests of natural therapy, Tibetan yogurt or fresh broccoli, for Helicobacter pylori infection. Methods Find Exp Clin Pharmacol. 2005 Jun; 27(5):327-9.
    View in: PubMed
    Score: 0.257
  6. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter. 2005 Feb; 10(1):1-3.
    View in: PubMed
    Score: 0.251
  7. Urea breath testing and analysis in the primary care office. J Fam Pract. 2002 Dec; 51(12):1030-2.
    View in: PubMed
    Score: 0.216
  8. Helicobacter pylori infection in children of Texas. J Pediatr Gastroenterol Nutr. 2000 Oct; 31(4):405-10.
    View in: PubMed
    Score: 0.186
  9. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 1999 Jan; 13(1):35-42.
    View in: PubMed
    Score: 0.165
  10. Lack of dose-response with Pancrease MT for the treatment of exocrine pancreatic insufficiency in adults. Aliment Pharmacol Ther. 1997 Oct; 11(5):981-6.
    View in: PubMed
    Score: 0.151
  11. [13C]Aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci. 1995 Nov; 40(11):2417-22.
    View in: PubMed
    Score: 0.132
  12. Reply to Kirby et al. J Infect Dis. 2015 Jan 01; 211(1):167.
    View in: PubMed
    Score: 0.121
  13. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis. 2014 Apr 01; 209(7):1016-22.
    View in: PubMed
    Score: 0.116
  14. Antimony electrodes for in vivo pH monitoring. Dig Dis Sci. 1991 Aug; 36(8):1180-1.
    View in: PubMed
    Score: 0.099
  15. Antimony electrodes. Mucosal potential differences and buffer composition adversely affect pH measurements in the stomach. Dig Dis Sci. 1990 Aug; 35(8):950-5.
    View in: PubMed
    Score: 0.092
  16. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):36-41.e1.
    View in: PubMed
    Score: 0.087
  17. Spicy food and the stomach. Evaluation by videoendoscopy. JAMA. 1988 Dec 16; 260(23):3473-5.
    View in: PubMed
    Score: 0.082
  18. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008 Oct; 14(10):1553-7.
    View in: PubMed
    Score: 0.081
  19. Visualization of the small intestine using capsule endoscopy in healthy subjects. Dig Dis Sci. 2007 Apr; 52(4):1019-25.
    View in: PubMed
    Score: 0.072
  20. Point-of-care Helicobacter pylori urine antibody detection in a multi-ethnic adult population in the United States. Transl Res. 2006 Jul; 148(1):13-8.
    View in: PubMed
    Score: 0.069
  21. Problem of distinguishing false-positive tests from acute or transient Helicobacter pylori infections. Helicobacter. 2006 Apr; 11(2):69-74.
    View in: PubMed
    Score: 0.068
  22. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006 Mar; 4(3):306-14.
    View in: PubMed
    Score: 0.068
  23. Improved infrared spectrophotometer for point-of-care patient 13C-urea breath testing in the primary care setting. Clin Biochem. 2005 Aug; 38(8):731-4.
    View in: PubMed
    Score: 0.065
  24. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun. 2005 May; 73(5):2999-3006.
    View in: PubMed
    Score: 0.064
  25. Effect of different organic acids (citric, malic and ascorbic) on intragastric urease activity. Aliment Pharmacol Ther. 2005 May 01; 21(9):1145-8.
    View in: PubMed
    Score: 0.064
  26. Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter. 2005 Apr; 10(2):136-8.
    View in: PubMed
    Score: 0.064
  27. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.063
  28. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005 Jan; 3(1):55-9.
    View in: PubMed
    Score: 0.063
  29. Lack of Detection of Norwalk Virus in Saliva Samples From a Controlled Human Infection Model. Open Forum Infect Dis. 2024 Nov; 11(11):ofae652.
    View in: PubMed
    Score: 0.062
  30. INTRA- AND INTER-HOST EVOLUTION OF HUMAN NOROVIRUS IN HEALTHY ADULTS. bioRxiv. 2024 Sep 05.
    View in: PubMed
    Score: 0.061
  31. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004 Sep; 53(9):1235-43.
    View in: PubMed
    Score: 0.061
  32. Migrating shell fragment as a cause of recurrent obscure gastrointestinal bleeding. J Clin Gastroenterol. 2004 Feb; 38(2):137-8.
    View in: PubMed
    Score: 0.059
  33. False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter. 2004 Feb; 9(1):17-27.
    View in: PubMed
    Score: 0.059
  34. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol. 2003 May; 98(5):1005-9.
    View in: PubMed
    Score: 0.056
  35. Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc. 2003 Apr; 57(4):626-7.
    View in: PubMed
    Score: 0.055
  36. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther. 2003 Jan; 17(2):193-200.
    View in: PubMed
    Score: 0.054
  37. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.045
  38. Norwalk virus vaccines: challenges and progress. J Infect Dis. 2000 May; 181 Suppl 2:S367-73.
    View in: PubMed
    Score: 0.045
  39. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000 Feb; 14(2):211-5.
    View in: PubMed
    Score: 0.044
  40. Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. Viruses. 2019 07 11; 11(7).
    View in: PubMed
    Score: 0.043
  41. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016 09 23; 353(6306):1387-1393.
    View in: PubMed
    Score: 0.035
  42. Recombinant Norwalk virus-like particles as an oral vaccine. Arch Virol Suppl. 1996; 12:243-9.
    View in: PubMed
    Score: 0.033
  43. Human Intestinal Enteroids: a New Model To Study Human Rotavirus Infection, Host Restriction, and Pathophysiology. J Virol. 2016 01 01; 90(1):43-56.
    View in: PubMed
    Score: 0.033
  44. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.032
  45. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis. BMC Immunol. 2015 Feb 10; 16:5.
    View in: PubMed
    Score: 0.031
  46. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis. 2015 Aug 01; 212(3):397-405.
    View in: PubMed
    Score: 0.031
  47. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol. 2015 Feb; 22(2):221-8.
    View in: PubMed
    Score: 0.031
  48. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis. 1994 Jul; 170(1):34-43.
    View in: PubMed
    Score: 0.030
  49. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol. 1993 Jun; 16(4):292-4.
    View in: PubMed
    Score: 0.028
  50. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol. 2012 Dec; 19(12):1980-3.
    View in: PubMed
    Score: 0.027
  51. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol. 2012 Feb; 19(2):284-7.
    View in: PubMed
    Score: 0.025
  52. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.025
  53. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol. 1991 Sep; 86(9):1158-62.
    View in: PubMed
    Score: 0.025
  54. Helicobacter pylori-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. Gastroenterology. 1991 Jun; 100(6):1571-5.
    View in: PubMed
    Score: 0.024
  55. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol. 2011 Jul; 18(7):1187-90.
    View in: PubMed
    Score: 0.024
  56. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010 Oct 15; 202(8):1212-8.
    View in: PubMed
    Score: 0.023
  57. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol. 1990 Apr; 85(4):394-8.
    View in: PubMed
    Score: 0.022
  58. Urea breath test in children: the United States prospective, multicenter study. Helicobacter. 2009 Apr; 14(2):134-40.
    View in: PubMed
    Score: 0.021
  59. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989 Mar; 96(3):683-9.
    View in: PubMed
    Score: 0.021
  60. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol. 1989 Mar; 84(3):233-8.
    View in: PubMed
    Score: 0.021
  61. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol Immunol. 1988 Dec; 1(3):117-25.
    View in: PubMed
    Score: 0.020
  62. Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis. 1988 Apr; 157(4):777-80.
    View in: PubMed
    Score: 0.020
  63. Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. FEMS Microbiol Immunol. 1988 Jan; 1(1):9-18.
    View in: PubMed
    Score: 0.019
  64. Epidemiology of Campylobacter pylori infection: ethnic considerations. Scand J Gastroenterol Suppl. 1988; 142:9-13.
    View in: PubMed
    Score: 0.019
  65. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1987 May 23; 1(8543):1174-7.
    View in: PubMed
    Score: 0.018
  66. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther. 2006 Jan 15; 23(2):295-301.
    View in: PubMed
    Score: 0.017
  67. Controlled comparison of topical anesthetic agents in flexible upper gastrointestinal endoscopy. Gastrointest Endosc. 1985 Aug; 31(4):255-8.
    View in: PubMed
    Score: 0.016
  68. Ranitidine and hepatotoxicity. Ann Intern Med. 1985 Mar; 102(3):416.
    View in: PubMed
    Score: 0.016
  69. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology. 1999 Jul; 117(1):40-8.
    View in: PubMed
    Score: 0.011
  70. Helicobacter pylori in the drinking water in Peru. Gastroenterology. 1996 Apr; 110(4):1031-5.
    View in: PubMed
    Score: 0.009
  71. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet. 1991 Jun 22; 337(8756):1503-6.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.